Abstract 146P
Background
Studies have classified muscle-invasive bladder cancer (MIBC) into primary (initially muscle-invasive, PMIBC) and secondary subtypes (initially non-muscle-invasive but progressed, SMIBC), in which controversial survival outcomes were demonstrated. However, a relevant Chinese cohort is yet to be reported.
Methods
Patients diagnosed with PMIBC or SMIBC at West China Hospital from January 2009 to June 2019 were retrospectively included. The Kruskal–Wallis and Fisher tests were employed to compare the baseline clinicopathological characteristics. Furthermore, Kaplan–Meier curves and Cox competing proportional risk model were used to compare the PMIBC and SMIBC survival outcomes. Then, propensity score matching (PSM) was employed to reduce the bias caused by confounders and subgroup analysis was used to confirm the outcomes.
Results
A total of 405 MIBC patients were enrolled, including 286 PMIBC and 119 SMIBC patients, with a mean age of 64.66 years and 67.29 years and a mean follow-up of 27.54 months and 53.3 months, respectively. The SMIBC group had a higher proportion of older patients (17.65% vs. 9.09%), chronic disease (32.77% vs. 22.38%), and neoadjuvant chemotherapy (19.33% vs. 8.04%). Before matching, SMIBC had a lower risk of overall mortality (OM) (hazard ratios [HR] 0.60, 95% confidence interval [CI] 0.41–0.85, P = 0.005) and cancer-specific mortality (CSM) (HR 0.64, 95% CI 0.44–0.94, P = 0.022) after the initial diagnosis. However, higher risks of OM (HR 1.47, 95% CI 1.02–2.10, P = 0.038) and CSM (HR 1.58, 95% CI 1.09–2.29, P = 0.016) were observed for SMIBC once it became muscle-invasive. After PSM, the baseline characteristics of 146 patients (73 for each group) were well matched, and SMIBC was confirmed to have an increased CSM risk (HR 1.83, 95% CI 1.09–3.06, P = 0.021) than PMIBC after muscle invasion.
Conclusions
This study demonstrated that SMIBC, compared with PMIBC, had worse survival outcomes once it became muscle-invasive and suggested that specific attention should be paid to non-muscle-invasive bladder cancer with a high progression risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis
Presenter: Hao-Wen Chuang
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03